Coventry and Warwickshire Area Prescribing Committee
Formulary
10 Musculoskeletal and joint diseases
10-01-03 Sulfasalazine
Sulfasalazine
Formulary
Treatment of active rheumatoid arthritis
Sulfasalazine - shared care agreement
Links
APC SCA023: Methotrexate - shared care agreement
Azathioprine - shared care agreement
Ciclosporin - shared care agreement
Gold - share care agreement
Hydroxychloroquine - shared care agreement
Leflunomide - shared care agreement
NICE CG177: Osteoarthritis - care and management
NICE CG79: Rheumatoid arthritis in adults: management
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
NICE TA220: Psoriatic arthritis - golimumab
NICE TA225: Rheumatoid arthritis - golimumab
NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA375: Rheumatoid arthritis
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
NICE TA518: Tocilizumab for treating giant cell arteritis
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Penicillamine - shared care agreement
Sulfasalazine - shared care agreement
Key
Full Site